QSAR study of androstenedione analogs as aromatase inhibitors

Letters in Drug Design and Discovery

Volumn 6, Issue 8, 2009, Pages 554-562

  Oliveira, Aline A ^a   Ramalho, Teodorico C ^a   Da Cunha, Elaine F F ^a  

^a FEDERAL UNIVERSITY OF LAVRAS   (Brazil)

Author keywords

5D QSAR; Androstenedione; Aromatase; Cancer; Medicinal chemistry

Indexed keywords

ANDROSTENEDIONE DERIVATIVE; AROMATASE INHIBITOR;

ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG CONFORMATION; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 70349200899     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018009789353464     Document Type: Article

References (36)

1. Garcia, M.; Jemal, A.; Ward, E.M.; Center, M.M.; Hao, Y.; Siegel, R.L.; Thun, M.J. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society, 2007.
2. Brasil, Ministério da Saúde, Secretaria de Atenção à Saúde. Instituto Nacional de Câncer, Coordenação de Prevenção e Vigilância de Câncer, Estimativas 2008: Incidência de Câncer no Brasil, INCA, Rio de Janeiro, 2007.
3. Buijs, C.; Vries, E.G.E.; Mourits, M.J.E.; Willemse, P.H.B. The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat. Rev., 2008, 34, 640-655.
4. Santen, R.J.; Manni, A.; Harvey, H.; Redmond, C. Endocrine treatment of breast cancer in women. Endocr. Rev., 1990, 11, 1-45. (Pubitemid 20182870)
5. van Landeghem, A.A.J.; Poortman, J.; Nabuurs, M.; Thijssen, J.H.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res., 1985, 45, 2900-2906. (Pubitemid 15232767)
6. Reed, M.J.A.; Owen, M.; Lai, L.C.; Coldham, N.G.; Ghilchik, M.W.; Shaikh, N.A.; James, V.H.T. In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione. Int. J. Cancer, 1989, 44, 233-237.
7. Blankenstein, M.A.; Maitimu-Smeele, I.; Donker, G.H.; Daroszewski, J.; Milewicz, A.; Thijssen, J.H.H. On the significance of in situ production of ocstrogens in human breast cancer tissue. J. Steroid Biochem. Mol. Biol., 1992, 41, 891-896.
8. Jong, P.C.; van de Ven, J.; Nortier, H.W.R.; Maitimu-Smeele, I.; Donker, T.H.; Thijssen, J.H.H.; Slee, P.H.T.J.; Blankenstein, R.A. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third- generation aromatase inhibitor vorozole. Cancer Res., 1997, 57, 2109-2111.
9. Kijima, I.; Phung, S.; Hur, G.; Kwok, Sum-Ling; Chen, S. Grape Seed Extract Is an Aromatase Inhibitor and a Suppressor of Aromatase Expression. Cancer Res., 2006, 66, 5960-5967. (Pubitemid 43927152)
10. Kellis Jr., J.T.; Vickery, L.E. Purification and characterization of human placental aromatase cytochrome P-450. J. Biol. Chem., 1987, 262, 4413-4420. (Pubitemid 17102645)
11. Miller, W.R.; Bartlett, J.; Brodie, A.M.H.; Brueggemeier, R.W.; Di Salle, E.; Lønning, P.E.; Llombart, A.; Maass, N.; Maudelonde, T.; Sasano, H.; Goss, P.E. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist, 2008, 13, 829-837.
12. Campos, S.M. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist, 2004, 9, 126-136. (Pubitemid 38452112)
13. Numazawa, M.; Oshibe, M.; Yamaguchi, S. 6-Alkylandrosta-4,6-diene-3,17- diones and their 1,4,6-triene analogs as aromatase inhibitors. Steroids, 1997, 62, 595-602.
14. Harper-Wynne, C.; Dowsett, M. Recent advances in the clinical application of aromatase inhibitors. J. Steroid Biochem. Mol. Biol., 2001, 76, 179-186. (Pubitemid 32510680)
15. Lønning, P.E. Pharmacology of new aromatase inhibitors. Breast, 1996, 5, 202-208.
16. Buzdar, A.U. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist, 2003, 8, 335-341. (Pubitemid 36934482)
17. Altundag, K.; Ibrahim, N.K. Aromatase Inhibitors in Breast Cancer: An Overview. Oncologist, 2006, 11, 553-562. (Pubitemid 43967611)
18. Numazawa, M.; Nagaoka, M.; Handa, W.; Ogawa, Y.; Matsuoka, S. Studies directed towards a mechanistic evaluation of inactivation of aromatase by the suicide substrates androsta-1,4-diene-3,17- diones and its 6-ene derivatives Aromatase inactivation by the 19- substituted derivatives and their enzymic aromatization. J. Steroid Biochem. Mol. Biol., 2007, 107, 211-219. (Pubitemid 47380379)
19. Numazawa, M.; Handa, W.; Yamada, K. Synthesis and biochemical properties of 6-bromoandrostenedione derivatives with a 2,2-dimethyl or 2-methyl group as aromatase inhibitors. Biol. Pharm. Bull., 2004, 27, 1878-1882.
20. Numazawa, M.; Watari, Y.; Yamada, K.; Umemura, N.; Handa, W. Probing the active site of aromatase with 2-methyl-substituted androstenedione analogs. Steroids, 2003, 68, 503-513. (Pubitemid 36945405)
21. Numazawa, M.; Handa, W.; Hasegawa, C.; Takahashi, M. Structure-activity relationships of 2α-substituted androstenedione analogs as aromatase inhibitors and their aromatization reactions. J. Steroid Biochem. Mol. Biol., 2005, 97, 353-359. (Pubitemid 41619414)
22. Nagaoka, M.; Watari, Y.; Yajima, H.; Tsukioka, K.; Muroi, Y.; Yamada, K.; Numazawa, M. Structure-activity relationships of 3-deoxy androgens asaromatase inhibitors. synthesis and biochemical studies of 4-substituted 4-ene and 5-ene steroids. Steroids, 2003, 68, 533-542. (Pubitemid 36945408)
23. Kubinyi, H. In Burger's Medicinal Chemistry and Drug Discovery; Wolff, M.E., Ed.; John Wiley & Sons. Inc.: New York, 1995, pp. 497-571.
24. Lill, M.A.; Vedani, A.; Dobler, M. Raptor: Combining dual-shell representation, induced-fit simulation, and hydrophobicity scoring in receptor modeling: application toward the simulation of structurally diverse ligand sets. J. Med. Chem., 2004, 47, 6174-6186.
25. Wavefunction, Inc., PC Spartan Pro, Irvine, USA, 1999.
26. Biographics Laboratory 3R, MacBio GL, Version 3.1, Copyright 2006-2008, Basel, Switzerland.
27. Romeiro, N.C.; Albuquerque, M.G; Alencastro, R.B.; Hopfinger, A.J. Construction of 4D-QSAR models for use in the design of novel p38-MAPK inhibitors. J. Comput. Aided Mol. Des., 2005, 19, 385-400.
28. Lill, M.A.; Vedani, A. Combining 4D pharmacophore generation and multidimensional QSAR: Modeling ligand binding to the Bradykinin B2 receptor. J. Chem. Inf. Model., 2006, 46, 2135-2145. (Pubitemid 44625984)
29. Lill, M.A.; Winiger, F.; Vedani, A.; Ernst, B. Impact of induced fit on ligand binding to the androgen receptor: A multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals. J. Med. Chem., 2005, 48, 5666-5674. (Pubitemid 41298341)
30. Vedani, A.; Dobler, M.; Dollinger, H.; Hasselbach, Kai-Malte; Birke, F.; Lill, M.A. Novel ligands for the chemokine receptor-3 (CCR3): A receptor-modeling study based on 5D-QSAR. J. Med. Chem., 2005, 48, 1515-1527.
31. da Cunha, E.F.F.; Martins, R.C.A.; Albuquerque, M.G.; Alencastro, R.B. LIV-3D-QSAR model for estrogen receptor ligands. J Mol. Model., 2004, 10, 297-304.
32. da Cunha, E.F.F.; Albuquerque, M.G.; Antunes, O.A.C.; Alencastro, R.B. 4D-QSAR Models of HOE/BAY-793 Analogues as HIV-1 Protease Inhibitors. QSAR Comb. Sci., 2005, 24, 240-253.
33. Josa, D.; da Cunha, E.F.F.; Ramalho, T.C.; Souza, T.C.S.; Caetano, M.S. Homology modeling of wild-type, D516V, and H526L Mycobacterium tuberculosis RNA polymerase and their molecular docking study with inhibitors. J. Biomol. Struct. Dyn. 2008, 25, 373-1345
34. da Cunha, E.F.F.; Ramalho, T.C.; Taft, C.A.; de Alencastro, R.B. Computer-assisted analysis of the interactions of macrocyclic inhibitors with wild type and mutant D168A hepatitis C virus NS3 serine protease. Lett. Drug Des. Discov., 2006, 3, 17-28.
35. Muri, E.M.F.; Gomes, M.; Costa, J.S.; Alencar, F.L.; Sales, A.; Bastos, M.L.; Hernandez-Valdes, R.; Albuquerque, M.G.; da Cunha, E.F.F.; Alencastro, R.B.; Williamson, J.S.; Antunes, O.A.C. N-t-Boc-amino acid esters of isomannide - Potential inhibitors of serine proteases. Amino Acids, 2004, 27(2), 153-159 Published: OCT 2004.
36. Brueggemeier, R.W.; Hackett, J.C.; Diaz-Cruz, E. S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev., 2005, 26, 331-345. (Pubitemid 40686647)